Colorectal Carcinoma Clinical Trial
Official title:
Increasing CRC Screening Using Audio and Video Brochures: A Pilot Randomized Controlled Trial
Verified date | December 2023 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial compares audio brochures and video brochures to usual care for increasing colorectal cancer (CRC) screening among adults living in Appalachia. Adults living in rural Appalachia experience increased rates of CRC, possibly due to the unique barriers to screening this population faces, such as lower socioeconomic status, limited health literacy, and less access to healthcare. The fecal immunochemical test (FIT) is a common CRC screening technique which allows individuals to complete the test at home and mail the kit back. A limitation of the current process for FIT screening outreach is that the instruction materials are heavy in text and not appropriate for individuals with limited health literacy. The audio and video brochures used in this clinical trial are instruction materials that have been specially designed to be appropriate for individuals of all health literacy levels. Providing these audio and video brochures with the FIT kits may increase CRC screening among adults living in Appalachia, compared to usual care.
Status | Completed |
Enrollment | 94 |
Est. completion date | February 1, 2022 |
Est. primary completion date | February 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 64 Years |
Eligibility | Inclusion Criteria: - Mid-life men and women (50-64 years old) - Live in Appalachia - Had a medical visit in the past two years - Are at average-risk for CRC (no history of CRC, polyps, inflammatory bowel disease, family history of CRC or hereditary CRC syndromes) - Are not within CRC screening guidelines (no fecal occult blood test/FIT in the past year; flexible sigmoidoscopy in past five years; colonoscopy in past ten years) |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center | National Institute on Aging (NIA) |
United States,
Katz ML, Shoben AB, Newell S, Hall C, Emerson B, Gray DM 2nd, Chakraborty S, Reiter PL. Video brochures in a mailed fecal immunochemical test outreach program provide cancer screening information in a user-friendly format for rural Appalachian community m — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants to Return Fecal Immunochemical Test (FIT) | Will estimate FIT return using proportions for each study group. Both comparisons (each intervention compared to control) will be a two-sample test of proportions (intent-to-treat analysis) using a one-sided alpha of 0.1 due to the preliminary nature of the study. | At 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04444232 -
Cancer Communication Within Hispanic Social Networks
|
N/A | |
Recruiting |
NCT06233253 -
Online Mindfulness-Based Intervention to Decrease Pre-Procedural Anxiety Before a First-Time Screening Colonoscopy
|
N/A | |
Recruiting |
NCT05799820 -
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
|
Phase 2 | |
Recruiting |
NCT04666727 -
Role of Diet on the Microbiome of the Digestive System
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Recruiting |
NCT02376452 -
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
Phase 2 | |
Completed |
NCT02254486 -
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults
|
Phase 3 | |
Completed |
NCT01486251 -
Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
|
N/A | |
Terminated |
NCT01233544 -
Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases
|
Phase 3 | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Completed |
NCT00704600 -
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00485316 -
Laparoscopic Assisted Versus Open Resection for Colorectal Carcinoma
|
Phase 3 | |
Recruiting |
NCT04430738 -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
Completed |
NCT05022511 -
Three Birds With One Stone
|
N/A | |
Not yet recruiting |
NCT03969784 -
Microparticles in Peritoneal Carcinomatosis of Colorectal Origin
|
N/A | |
Completed |
NCT04607291 -
Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening
|
Phase 1 | |
Not yet recruiting |
NCT05630794 -
Testing ONC201 to Prevent Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT05291988 -
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
|
N/A | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 |